Eli Lilly (LLY) is trading at $1,356.25, down 1.08% over 24 hours, while the stock still sits close to the upper end of its recent range and well above its 50-day moving average. The setup is mixed...
Eli Lilly’s latest reported catalyst is the October 29, 2026 third-quarter update: revenue rose 39% year over year to $24.4 billion, adjusted EPS came in at $7.48, and management lifted full-year 2026 revenue guidance to $91.0 billion to $92.0 billion while also raising underlying non-GAAP EPS guidance. That matters because the market is still anchoring the stock to execution in obesity and diabetes, where Mounjaro and Zepbound remain the main revenue engines. citeturn0search0
RBC Capital reiterated an Outperform rating and a $1,600 target on November 17, 2026, while Barclays raised its target to $1,550 on November 16, 2026. Stockanalysis.com, citing 31 analysts polled by S&P Global, shows a consensus Buy rating and an average target of $1,470, with a wide range from $940 to $1,700. That spread says the market is still rewarding Lilly’s growth profile, but the path higher is not being priced as a straight line. citeturn0search1turn0search2turn0search3
At $1,356.25, LLY is trading below the 7-day SMA of $1,399.02, the 20-day SMA of $1,403.22, the 12-day EMA of $1,393.00, and the 26-day EMA of $1,374.24. That is a short-term distribution pattern, but the stock remains above the 50-day SMA of $1,306.70, which keeps the medium-term trend intact. citeturn0search4
Momentum is soft rather than broken. 64. In plain terms, the stock has lost upside momentum, but the indicator mix does not yet confirm a full trend reversal.
Source link







